Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HROW with free AI briefings, catalyst countdowns, and dilution alerts.

HROW · HARROW, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$75.3M Cash on Hand
24.6mo Cash Runway
Follow HROW by email Get an email when HROW reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HROW, unsubscribe in one click. Privacy

📣 What HROW Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fluorometholone Acetate
FDA approved Feb 1986 · Flarex
Ocular Inflammation Phase 4 · NCT07588074 Completed
Cyclosporine 0.1% Ophthalmic Solution Dry Eye Disease (DED) N/A · NCT07904728 Recruiting
Chloroprocaine Hydrochloride Ophthalmic Gel Antiseptic Phase 4 · NCT05934253 Completed
Chloroprocaine ophthalmic gel 3% Diabetic Macular Edema (DME) Phase 4 · NCT07456826 Enrolling by invitation
Cyclosporine emulsion Dry Eye Disease (DED) Phase 4 · NCT07368595 Not yet recruiting
Lidocaine pledget Macular Degeneration Phase 4 · NCT07779356 Completed
Proparacaine Hydrochloride Ophthalmic Solution… Diabetic Macular Edema (DME) Phase 4 · NCT07456826 Enrolling by invitation
Cyclosporine Ophthalmic Meibomian Gland Dysfunction (MGD) Phase 4 · NCT07224529 Recruiting
Triamcinolone Acetonide Postoperative Ocular Inflammation Phase 3 · NCT07832552 Enrolling by invitation

Also used in these trials (approved or third-party drugs, not HROW's own candidates): Ergocalciferol, Lidocaine Hydrochloride, Loteprednol Etabonate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HROW holds $75.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 24.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HROW files for a raise →

👥 Who Owns HROW

Insiders 17% Other 5%+ holders 7.7% Institutions (292 holders) 59.6% Public and other holders 15.7%
HolderTypeShares% of sharesAs of
Mark L Baum
CHIEF EXECUTIVE OFFICER, Director · +889,500 options
Insider 2,996,130 7.98% 2026-05-14
Daniel Kaufman 5%+ holder (13G) 2,898,254 7.72% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 2,757,783 7.35% 2026-09-30
Opaleye Management Inc.
10% owner
Insider 2,105,000 5.61% 2026-09-30
Andrew R. Boll
PRESIDENT AND CFO · +405,750 options
Insider 814,679 2.17% 2026-05-14
John P. Saharek
CEO & President, ImprimisRx
Insider 467,388 1.25% 2025-04-03
Lauren P Silvernail
Director · +5,248 options
Insider 1,000 0.00% 2026-05-18
Adrienne L Graves
Director · +5,248 options
Insider 1,000 0.00% 2026-05-18

Share count 37,533,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HROW picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HROW and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.